Aptevo Therapeutics is committed to building a robust pipeline of preclinical ADAPTIR™ bispecific candidates with a focus on novel mechanisms of action. By leveraging our proprietary ADAPTIR platform, these new candidates utilize multiple mechanisms of action, including redirected T-cell cytotoxicity (RTCC), T-cell co-stimulators, and targeted cytokine delivery to exploit new biological pathways for the discovery and development of novel cancer and autoimmune therapies.